Please ensure Javascript is enabled for purposes of website accessibility

Drug Combination Helps Alzheimer's Disease Patients in Pivotal Study

By Cory Renauer – Apr 27, 2020 at 11:13AM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

Clinical trial results suggest that an experimental treatment combining two already-approved drugs could make life easier for Alzheimer's patients and their caregivers.

An experimental treatment in late-stage development hit a bullseye in a clinical trial with Alzheimer's disease patients. Axsome Therapeutics' (AXSM 1.59%) lead treatment candidate, AXS-05 significantly reduced symptoms of Alzheimer's disease agitation during the pivotal Advance-1 study.

Around 6 million Americans have Alzheimer's disease, and this figure is expected to reach 14 million by 2050. AXS-05 does not treat dementia directly, but it could alleviate symptoms of agitation that affect around 70% of Alzheimer's disease patients.

Caregiver and elderly patient

Image source: Getty Images.

Alzheimer's disease agitation has been associated with accelerated cognitive decline, decreased functioning, and earlier nursing home placement. Frequent bouts of emotional distress, disinhibition, and disruptive irritability also make life extra difficult for caregivers.

Hitting the mark

AXS-05 is a combination of bupropion, a decades-old old antidepressant, and dextromethorphan, which is the main ingredient in most cough suppressants. 

The Advance-1 trial split 366 patients into groups that received either AXS-05, a placebo, or bupropion alone. Patients treated with a placebo showed less agitation than those treated with bupropion, which was a little surprising.

As hoped, patients in the AXS-05 group were significantly less agitated than both control groups without any serious side effects reported. In fact, there were patient deaths in both control groups, but none among those treated with AXS-05. 

A pivotal trial with AXS-05 as a treatment for treatment-resistant depression failed to meet its primary endpoint in March, but it did succeed in a pivotal major depressive disorder study. An application to treat major depressive disorder will probably reach the FDA in the fourth quarter.

Cory Renauer has no position in any of the stocks mentioned. The Motley Fool has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Axsome Therapeutics, Inc. Stock Quote
Axsome Therapeutics, Inc.
$45.33 (1.59%) $0.71

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning analyst team.

Stock Advisor Returns
S&P 500 Returns

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 10/03/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.